O

    Organon & Co (OGN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $13.76
    -0.00 (-0.04%)

    Market Cap: $3.61B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(15/22)
    Avg Surprise
    +6.00%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.88
    Range$0.88 - $0.88
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.93+5.9%
    60d ago$1.05+18.7%
    30d ago$1.05+18.7%
    7d ago$1.05+18.7%
    Current$0.88
    Revenue Consensus
    $1.6B
    Range$1.6B - $1.6B
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.53
    Range$0.50 - $0.56
    2 analysts
    Revenue Consensus
    $1.5B
    Range$1.5B - $1.6B
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.53---
    Sep 26EST
    		-$0.88---
    Jun 26
    Reported Jul 31
    		$0.80$0.85-5.88%Miss-20.0%
    Mar 26
    Reported Apr 30
    		$0.71$0.85-16.47%Miss-30.4%
    Dec 25
    Reported Feb 12
    		$0.63$0.73-13.70%Miss-30.0%
    Sep 25
    Reported Nov 10
    		$1.01$0.93+8.60%Beat+16.1%
    Jun 25
    Reported Aug 5
    		$1.00$0.94+6.38%Beat-10.7%
    Mar 25
    Reported May 1
    		$1.02$0.89+14.61%Beat-16.4%
    Dec 24
    Reported Feb 13
    		$0.90$0.87+3.45%Beat+2.3%
    Sep 24
    Reported Oct 31
    		$0.87$0.90-3.33%Miss+0.0%
    Jun 24
    Reported Aug 6
    		$1.12$1.08+3.70%Beat-14.5%
    Mar 24
    Reported May 2
    		$1.22$0.93+31.18%Beat+13.0%
    Dec 23
    Reported Feb 15
    		$0.88$0.83+6.02%Beat+8.6%
    Sep 23
    Reported Nov 2
    		$0.87$1.06-17.92%Miss-34.1%
    Jun 23
    Reported Aug 8
    		$1.31$0.99+32.32%Beat+4.8%
    Mar 23
    Reported May 4
    		$1.08$1.16-6.90%Miss-34.5%
    Dec 22
    Reported Feb 16
    		$0.81$0.90-10.00%Miss-40.9%
    Sep 22
    Reported Nov 3
    		$1.32$1.10+20.00%Beat-21.0%
    Jun 22
    Reported Aug 4
    		$1.25$1.19+5.04%Beat-27.3%
    Mar 22
    Reported May 5
    		$1.65$1.30+26.92%Beat+4.4%
    Dec 21
    Reported Feb 17
    		$1.37$1.27+7.87%Beat-
    Sep 21
    Reported Nov 11
    		$1.67$1.44+15.97%Beat-
    Jun 21
    Reported Aug 12
    		$1.72$1.43+20.28%Beat-
    Mar 21
    Reported Jun 21
    		$1.58$1.52+3.95%Beat-

    Dividends

    Dividend Metrics

    Yield0.58%
    Annual/Share$0.08
    Payout Ratio2.85%
    Frequency4
    Pay MonthsMar, Jun, Sep, Dec

    Growth

    3Y CAGR-62.30%
    View OGN's full dividend history

    Key Metrics

    Valuation
    P/E Ratio4.37EV/EBITDA8.40x
    Price/FCF6.37xFCF Yield15.70%
    Profitability
    Profit Margin3.41%Operating Margin20.70%
    ROE24.00%ROIC6.44%
    Financial Health
    Debt/Equity8.50xInterest Coverage2.08x
    Current Ratio1.95xQuick Ratio1.44x
    Trading Statistics
    Beta1.52Avg Volume2.89M
    52-Week High$13.7752-Week Low$5.67

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.74
    SMA 20$13.68
    SMA 50$13.57
    SMA 200$10.14
    EMA 10$13.74
    EMA 20$13.69
    EMA 50$13.42
    EMA 200$11.43

    MACD

    Line: 0.07Signal: 0.07Hist: -0.00

    ADX

    ADX: 56.3+DI: 21.0-DI: 7.8

    Aroon & PSAR

    Aroon Up100.0
    Aroon DownN/A
    PSAR$13.73

    Bollinger Bands

    Upper Band$13.85
    Lower Band$13.52
    %B Position241%(Upper)
    Band Width0.72

    RSI (14-Day)

    Overbought
    72.6

    Momentum Oscillators

    Stoch %K92.2
    Stoch %D95.1
    Williams %R-12.5
    ROC (10d)0.4%
    Momentum0.06
    CCI (20d)77.7
    MFI (14d)65.3

    Volatility Measures

    ATR (14d)$0.04(0.3%)
    StdDev (20d)0.08
    Hist Vol2.7%(Low)

    Volume Flow

    VWAP$13.76
    OBV231.9M
    AD Line-943.9M
    CMF (20d)-0.206

    Volume Metrics

    Avg Vol (20d)2.9M
    Vol Ratio1.4x
    VWMA (20d)$13.69

    Pivot Points

    R3$13.78
    R2$13.77
    R1$13.77
    Pivot Point$13.76
    S1$13.76
    S2$13.75
    S3$13.75

    Advanced Oscillators

    TSI46.98
    Ultimate Osc56.5
    KST15.71

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.56B$1.46B$1.51B$1.60B$1.59B$1.51B$1.59B$1.58B$1.61B$1.62B$1.60B$1.52B
    Cost of Revenue$711.00M$677.00M$766.00M$745.00M$720.00M$672.00M$696.00M$659.00M$668.00M$665.00M$683.00M$612.00M
    Gross Profit$847.00M$783.00M$741.00M$857.00M$874.00M$841.00M$896.00M$923.00M$939.00M$957.00M$915.00M$907.00M
    Operating Expenses$525.00M$548.00M$832.00M$499.00M$550.00M$608.00M$608.00M$584.00M$568.00M$581.00M$661.00M$675.00M
    R&D$91.00M$93.00M$91.00M$84.00M$95.00M$102.00M$130.00M$162.00M$131.00M$127.00M$134.00M$137.00M
    SG&A$434.00M$424.00M$433.00M$415.00M$453.00M$420.00M$470.00M$422.00M$437.00M$431.00M$469.00M$538.00M
    Operating Income$322.00M$235.00M$-91,000,000$358.00M$324.00M$233.00M$288.00M$339.00M$371.00M$376.00M$254.00M$232.00M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$108.00M$111.00M$109.00M$128.00M$131.00M$124.00M$132.00M$126.00M$131.00M$131.00M$128.00M$134.00M
    Income Before Tax$183.00M$213.00M$-148,000,000$243.00M$229.00M$101.00M$129.00M$207.00M$235.00M$236.00M$104.00M$80.00M
    Income Tax Expense$75.00M$67.00M$57.00M$83.00M$84.00M$14.00M$20.00M$-152,000,000$40.00M$35.00M$-442,000,000$22.00M
    Net Income$108.00M$146.00M$-205,000,000$160.00M$145.00M$87.00M$109.00M$359.00M$195.00M$201.00M$546.00M$58.00M
    EBITDA$371.00M$410.00M$57.00M$463.00M$449.00M$309.00M$338.00M$402.00M$432.00M$432.00M$292.00M$275.00M
    EBIT$291.00M$324.00M$-39,000,000$371.00M$360.00M$225.00M$261.00M$333.00M$366.00M$367.00M$232.00M$214.00M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about OGN

    News

    Organon & Co. (OGN) Short Interest & Short Float | Updated Aug 2026 $OGN

    As of August 14, 2026, Organon & Co. (OGN) had a short interest of 15.14 million shares, a 9.92% decrease from the prior report, representing 5.86% of its public float. The short interest ratio is 6.1 days to cover. This report details the historical short interest data for OGN, along with comparisons to peers and explanations of key short interest metrics.

    MarketBeat•8/28/26•
    Neutral

    Organon earnings up next: Can drugmaker rebound after Q1 miss?

    Organon & Co. is set to report second-quarter earnings, with investors keen to see if the women's health drugmaker can recover from a disappointing first quarter. The report comes amidst a pending acquisition by Sun Pharmaceutical, which adds complexity to the company's future outlook. Analysts hold a neutral stance on the stock, citing skepticism about growth prospects despite recent product developments.

    Investing.com•8/24/26•
    Neutral

    Organon earnings up next: Can drugmaker rebound after Q1 miss?

    Organon & Co. is set to report second-quarter earnings, with analysts expecting improved sequential performance but a year-over-year decline. The report will be crucial for the women's health drugmaker to demonstrate a rebound after a disappointing first quarter, especially as its pending acquisition by Sun Pharmaceutical adds an element of uncertainty. Investors will be scrutinizing the performance of its core women's health franchise and management commentary on biosimilars and established brands.

    Investing.com•8/23/26•
    Somewhat-Bearish

    Organon & Co stock hits 52-week high at 13.73 USD

    Organon & Co (OGN) stock has reached a new 52-week high of $13.73, following an 83% surge over the past six months and 92% year-to-date returns. InvestingPro analysis suggests the stock is still undervalued with a fair value of $20.04, highlighting strong free cash flow and shareholder yield. The company has also expanded its product portfolio with FDA-approved biosimilars and licensing agreements.

    Investing.com•8/19/26•
    Bullish

    how InvestingPro’s Fair Value spotted Organon’s 69% gain potential By Investing.com

    InvestingPro's Fair Value analysis successfully identified Organon & Co. (NYSE:OGN) as a significantly undervalued stock in early February 2026, predicting a substantial upside potential when it was trading at $8.00 per share. The analysis proved accurate, as the stock surged 68.75% to $13.50 by late June 2026, driven by factors like acquisition rumors, a cleared audit, and new product approvals. This case highlights how InvestingPro's comprehensive valuation methodology can uncover investment opportunities missed by the broader market.

    Investing.com•8/15/26•
    Bullish

    Frequently Asked Questions About OGN

    What is OGN's current dividend yield?
    Organon & Co (OGN) has a current dividend yield of 0.58%.
    Does OGN pay dividends?
    Yes, Organon & Co pays dividends with a current yield of 0.58%.
    What is OGN's P/E ratio?
    Organon & Co has a price-to-earnings (P/E) ratio of 4.37.
    What is OGN's market cap?
    Organon & Co (OGN) has a market capitalization of $3.61B with a current stock price of $13.76.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In